Mylan and Biocon announced this week that they have launched their biosimilar trastuzumab, Ogivri, in Australia. Ogivri, referencing Herceptin, is the first trastuzumab biosimilar to launch in the Australian marketplace and is listed on the nation’s Pharmaceutical Benefit Scheme.
Mylan and Biocon announced this week that they have launched their biosimilar trastuzumab, Ogivri, in Australia. Ogivri, referencing Herceptin, is the first trastuzumab biosimilar to launch in the Australian marketplace and is listed on the nation’s Pharmaceutical Benefit Scheme (PBS).
Sylvain Vigneault, Mylan’s Australia country manager, said in a statement announcing the launch, “As a global leader in the development of complex products, including biosimilar medicines, we’re pleased to launch our first biosimilar in Australia.” Vigneault added, “Biosimilars increase timely and affordable patient access to the latest treatments and help deliver a sustainable PBS. Mylan’s investment in biosimilars is an exciting evolution in how we can treat Australian patients. We are delighted that Ogivri enables Mylan, with our partner Biocon, to bring this treatment option to Australian patients with HER2-positive breast and gastric cancers.”
While the biosimilar is listed on the PBS and is therefore subsidized by the government, the product is not currently “a-flagged,” or substitutable at the pharmacy level. Australia’s “a-flag” system allows a biosimilar and a reference product to be substituted for one another by a pharmacist for indications that they share, although prescribers retain the right to prevent substitution. To date, only biosimilars that treat inflammatory diseases (2 infliximab biosimilars and an etanercept biosimilar) are “a-flagged.”
Also approved (but not yet launched) in Australia are biosimilar trastuzumab products developed by Celltrion (registered under the names Simbatra, Herzuma, and Hertuzu), Samsung Bioepis (registered under the name Ontruzant), and Amgen (registered under the name Kanjinti).
Ogivri is also approved in the United States, although it has yet to launch. To date, in the US context, only Amgen’s Kanjinti competes with the reference Herceptin.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.